AstraZeneca shares take historic tumble on failed lung cancer study
July 27, 2017 at 09:12 AM EDT
AstraZeneca shares fell 15 percent after disappointing results for a lung cancer treatment in highly anticipated clinical trial.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|